BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, Mollenhauer B, Blennow K, Calabresi P. CSF and blood biomarkers for Parkinson's disease. Lancet Neurol 2019;18:573-86. [PMID: 30981640 DOI: 10.1016/S1474-4422(19)30024-9] [Cited by in Crossref: 198] [Cited by in F6Publishing: 236] [Article Influence: 66.0] [Reference Citation Analysis]
Number Citing Articles
1 Cardinale A, Calabrese V. The intricate debate on neurodegeneration and neuroinflammation in Parkinson’s disease: which came first? Neural Regen Res 2023;18:125. [DOI: 10.4103/1673-5374.343895] [Reference Citation Analysis]
2 Steffen F, Uphaus T, Ripfel N, Fleischer V, Schraad M, Gonzalez-escamilla G, Engel S, Groppa S, Zipp F, Bittner S. Serum Neurofilament Identifies Patients With Multiple Sclerosis With Severe Focal Axonal Damage in a 6-Year Longitudinal Cohort. Neurol Neuroimmunol Neuroinflamm 2023;10:e200055. [DOI: 10.1212/nxi.0000000000200055] [Reference Citation Analysis]
3 Cho E, Kim K, Kim H, Cho S. Reelin protects against pathological α-synuclein accumulation and dopaminergic neurodegeneration after environmental enrichment in Parkinson's disease. Neurobiology of Disease 2022;175:105898. [DOI: 10.1016/j.nbd.2022.105898] [Reference Citation Analysis]
4 Nila IS, Sumsuzzman DM, Khan ZA, Jung JH, Kazema AS, Kim SJ, Hong Y. Identification of exosomal biomarkers and its optimal isolation and detection method for the diagnosis of Parkinson's disease: A systematic review and meta-analysis. Ageing Research Reviews 2022;82:101764. [DOI: 10.1016/j.arr.2022.101764] [Reference Citation Analysis]
5 Wang Q, Botchway BO, Zhang Y, Liu X. Ellagic acid activates the Keap1-Nrf2-ARE signaling pathway in improving Parkinson’s disease: A review. Biomedicine & Pharmacotherapy 2022;156:113848. [DOI: 10.1016/j.biopha.2022.113848] [Reference Citation Analysis]
6 Xiang C, Cong S, Tan X, Ma S, Liu Y, Wang H, Cong S. A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson’s disease. npj Parkinsons Dis 2022;8:165. [DOI: 10.1038/s41531-022-00431-7] [Reference Citation Analysis]
7 Tao M, Dou K, Xie Y, Hou B, Xie A. The associations of cerebrospinal fluid biomarkers with cognition, and rapid eye movement sleep behavior disorder in early Parkinson’s disease. Front Neurosci 2022;16. [DOI: 10.3389/fnins.2022.1049118] [Reference Citation Analysis]
8 Wang K, Shen J, Xu Y. An Update on Peripheral Blood Extracellular Vesicles as Biomarkers for Parkinson's Disease Diagnosis. Neuroscience 2022. [DOI: 10.1016/j.neuroscience.2022.11.017] [Reference Citation Analysis]
9 Liu G, Yu Z, Gao L, Zheng Y, Feng T. Erythrocytic alpha-synuclein in early Parkinson's disease: A 3-year longitudinal study. Parkinsonism & Related Disorders 2022;104:44-48. [DOI: 10.1016/j.parkreldis.2022.09.011] [Reference Citation Analysis]
10 Zhang X, Fan W, Yu H, Li L, Chen Z, Guan Q. Single- and dual-task gait performance and their diagnostic value in early-stage Parkinson's disease. Front Neurol 2022;13:974985. [DOI: 10.3389/fneur.2022.974985] [Reference Citation Analysis]
11 Nabizadeh F, Pirahesh K, Ramezannezhad E. Longitudinal striatal dopamine transporter binding and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in Parkinson’s disease. Neurol Sci 2022. [DOI: 10.1007/s10072-022-06440-x] [Reference Citation Analysis]
12 Zheng Y, Cai H, Zhao J, Yu Z, Feng T. Alpha-Synuclein species in oral mucosa as potential biomarkers for multiple system atrophy. Front Aging Neurosci 2022;14:1010064. [DOI: 10.3389/fnagi.2022.1010064] [Reference Citation Analysis]
13 Åström DO, Simonsen J, Raket LL, Sgarbi S, Hellsten J, Hagell P, Norlin JM, Kellerborg K, Martinez-Martin P, Odin P. High risk of developing dementia in Parkinson's disease: a Swedish registry-based study. Sci Rep 2022;12:16759. [PMID: 36202962 DOI: 10.1038/s41598-022-21093-8] [Reference Citation Analysis]
14 Nakajima K, Yamaguchi K, Noji M, Aguirre C, Ikenaka K, Mochizuki H, Zhou L, Ogi H, Ito T, Narita I, Gejyo F, Naiki H, Yamamoto S, Goto Y. Macromolecular crowding and supersaturation protect hemodialysis patients from the onset of dialysis-related amyloidosis. Nat Commun 2022;13:5689. [PMID: 36192385 DOI: 10.1038/s41467-022-33247-3] [Reference Citation Analysis]
15 Yoo D, Bang J, Ahn C, Nyaga VN, Kim Y, Kang MJ, Ahn T. Diagnostic value of α-synuclein seeding amplification assays in α-synucleinopathies: A systematic review and meta-analysis. Parkinsonism & Related Disorders 2022. [DOI: 10.1016/j.parkreldis.2022.10.007] [Reference Citation Analysis]
16 Morris HR. Blood based biomarkers for movement disorders. Acta Neurol Scand 2022;146:353-61. [PMID: 36156206 DOI: 10.1111/ane.13700] [Reference Citation Analysis]
17 Popp J, Georgescu D, Bürge M, Mundwiler-pachlatko E, Bernasconi L, Felbecker A. Biomarker in der Diagnostik kognitiver Störungen – Empfehlungen der Swiss Memory Clinics. Praxis 2022;111:738-744. [DOI: 10.1024/1661-8157/a003913] [Reference Citation Analysis]
18 Li R, Wang L, Duan H, Zhang Q, Guo X, Wu C, Peng W. Regulation of mitochondrial dysfunction induced cell apoptosis is a potential therapeutic strategy for herbal medicine to treat neurodegenerative diseases. Front Pharmacol 2022;13:937289. [DOI: 10.3389/fphar.2022.937289] [Reference Citation Analysis]
19 Mo M, Qiu J, Tang Y, Wei L, Peng G, Lin Y, Dai W, Zhang Z, Chen X, Liu H, Ding L, Guo W, Xu P. Lipid metabolism disorder in cerebrospinal fluid related to Parkinson’s disease.. [DOI: 10.21203/rs.3.rs-2039971/v1] [Reference Citation Analysis]
20 Deng X, Saffari SE, Liu N, Xiao B, Allen JC, Ng SYE, Chia N, Tan YJ, Choi X, Heng DL, Lo Y, Xu Z, Tay K, Au W, Ng A, Tan E, Tan LCS. Biomarker characterization of clinical subtypes of Parkinson Disease. npj Parkinsons Dis 2022;8:109. [DOI: 10.1038/s41531-022-00375-y] [Reference Citation Analysis]
21 Dou K, Ma J, Zhang X, Shi W, Tao M, Xie A. Multi-predictor modeling for predicting early Parkinson’s disease and non-motor symptoms progression. Front Aging Neurosci 2022;14:977985. [DOI: 10.3389/fnagi.2022.977985] [Reference Citation Analysis]
22 Poewe W, Stankovic I, Halliday G, Meissner WG, Wenning GK, Pellecchia MT, Seppi K, Palma JA, Kaufmann H. Multiple system atrophy. Nat Rev Dis Primers 2022;8:56. [PMID: 36008429 DOI: 10.1038/s41572-022-00382-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Yang Y, Yuan Y, Zhang G, Wang H, Chen YC, Liu Y, Tarolli CG, Crepeau D, Bukartyk J, Junna MR, Videnovic A, Ellis TD, Lipford MC, Dorsey R, Katabi D. Artificial intelligence-enabled detection and assessment of Parkinson's disease using nocturnal breathing signals. Nat Med 2022. [PMID: 35995955 DOI: 10.1038/s41591-022-01932-x] [Reference Citation Analysis]
24 Zheng R, Yan Y, Pu J, Zhang B. Physiological and Pathological Functions of Neuronal Hemoglobin: A Key Underappreciated Protein in Parkinson's Disease. Int J Mol Sci 2022;23:9088. [PMID: 36012351 DOI: 10.3390/ijms23169088] [Reference Citation Analysis]
25 Kundu A. Identification of Potential Blood-based Biomarkers for Multiple Sclerosis.. [DOI: 10.1101/2022.08.08.22278573] [Reference Citation Analysis]
26 Barba L, Abu Rumeileh S, Bellomo G, Paolini Paoletti F, Halbgebauer S, Oeckl P, Steinacker P, Massa F, Gaetani L, Parnetti L, Otto M. Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2022. [DOI: 10.1136/jnnp-2022-329124] [Reference Citation Analysis]
27 Mehta NH, Suss RA, Dyke JP, Theise ND, Chiang GC, Strauss S, Saint-louis L, Li Y, Pahlajani S, Babaria V, Glodzik L, Carare RO, de Leon MJ. Quantifying cerebrospinal fluid dynamics: A review of human neuroimaging contributions to CSF physiology and neurodegenerative disease. Neurobiology of Disease 2022;170:105776. [DOI: 10.1016/j.nbd.2022.105776] [Reference Citation Analysis]
28 Liang H, Guo W, He H, Zhang H, Ye Q, Zhang Q, Liao J, Shen Y, Wang J, Xiao Y, Qin C. Decreased soluble Nogo-B in serum as a promising biomarker for Parkinson's disease. Front Neurosci 2022;16:894454. [DOI: 10.3389/fnins.2022.894454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Magalhães P, Lashuel HA. Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other synucleinopathies. NPJ Parkinsons Dis 2022;8:93. [PMID: 35869066 DOI: 10.1038/s41531-022-00357-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Koníčková D, Menšíková K, Tučková L, Hényková E, Strnad M, Friedecký D, Stejskal D, Matěj R, Kaňovský P. Biomarkers of Neurodegenerative Diseases: Biology, Taxonomy, Clinical Relevance, and Current Research Status. Biomedicines 2022;10:1760. [DOI: 10.3390/biomedicines10071760] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Goto Y, Noji M, Nakajima K, Yamaguchi K. Supersaturation-Dependent Formation of Amyloid Fibrils. Molecules 2022;27:4588. [DOI: 10.3390/molecules27144588] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Christenson PR, Li M, Rowden G, Schwabenlander MD, Wolf TM, Oh SH, Larsen PA. A field-deployable diagnostic assay for the visual detection of misfolded prions. Sci Rep 2022;12:12246. [PMID: 35851406 DOI: 10.1038/s41598-022-16323-y] [Reference Citation Analysis]
33 Wang L, Zhang W, Liu F, Mao C, Liu CF, Cheng W, Feng J. Association of Cerebrospinal Fluid Neurofilament Heavy Protein Levels With Clinical Progression in Patients With Parkinson Disease. JAMA Netw Open 2022;5:e2223821. [PMID: 35881392 DOI: 10.1001/jamanetworkopen.2022.23821] [Reference Citation Analysis]
34 Abdelmoaty MM, Machhi J, Yeapuri P, Shahjin F, Kumar V, Olson KE, Mosley RL, Gendelman HE. Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease. Clin Transl Med 2022;12:e958. [PMID: 35802825 DOI: 10.1002/ctm2.958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Minehan RL, Del Borgo MP. Controlled Release of Therapeutics From Enzyme-Responsive Biomaterials. Front Biomater Sci 2022;1. [DOI: 10.3389/fbiom.2022.916985] [Reference Citation Analysis]
36 Hall S, Orrù CD, Serrano GE, Galasko D, Hughson AG, Groveman BR, Adler CH, Beach TG, Caughey B, Hansson O. Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. Acta Neuropathol Commun 2022;10:90. [PMID: 35733234 DOI: 10.1186/s40478-022-01388-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
37 Tsukita K, Sakamaki-tsukita H, Kaiser S, Zhang L, Messa M, Serrano-fernandez P, Takahashi R. Changes in the cerebrospinal fluid proteome precede and stratify the course of Parkinson’s Disease.. [DOI: 10.1101/2022.06.08.22276035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Agnello L, Lo Sasso B, Vidali M, Scazzone C, Gambino CM, Piccoli T, Bivona G, Ciaccio AM, Giglio RV, La Bella V, Ciaccio M. Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders. J Clin Med 2022;11:3139. [PMID: 35683523 DOI: 10.3390/jcm11113139] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Zheng Y, Wang X, Zhao H, Jiang Y, Zhu Y, Chen J, Sun W, Wang Z, Sun Y. The “Black Straight-Line Sign” in the Putamen in Diffusion-Weighted Imaging: A Potential Diagnostic MRI Marker for Multiple System Atrophy. Front Neurol 2022;13:890168. [DOI: 10.3389/fneur.2022.890168] [Reference Citation Analysis]
40 Hall S, Orrù C, Serrano GE, Galasko D, Hughson AG, Groveman BR, Adler CH, Beach TG, Caughey B, Hansson O. PERFORMANCE OF αSYNUCLEIN RT-QUIC IN RELATION TO NEUROPATHOLOGICAL STAGING OF LEWY BODY DISEASE.. [DOI: 10.1101/2022.05.05.22274567] [Reference Citation Analysis]
41 Abdi IY, Ghanem SS, El-agnaf OM. Immune-related biomarkers for Parkinson's disease. Neurobiology of Disease 2022. [DOI: 10.1016/j.nbd.2022.105771] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Rosenstein I, Andersen O, Victor D, Englund E, Granberg T, Hedberg-Oldfors C, Jood K, Fitrah YA, Ikeuchi T, Danylaité Karrenbauer V. Four Swedish cases of CSF1R-related leukoencephalopathy: Visualization of clinical phenotypes. Acta Neurol Scand 2022;145:599-609. [PMID: 35119108 DOI: 10.1111/ane.13589] [Reference Citation Analysis]
43 Doroszkiewicz J, Groblewska M, Mroczko B. Molecular Biomarkers and Their Implications for the Early Diagnosis of Selected Neurodegenerative Diseases. Int J Mol Sci 2022;23:4610. [PMID: 35563001 DOI: 10.3390/ijms23094610] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
44 Munoz Ospina B, Quintana-peña V, Alvarez D, A. Valderrama J, Takeuchi Y, L. Orozco J. Perspectives of Cognitive Impairment and Behavioral Disturbances in Parkinson’s Disease Dementia. Dementia in Parkinson’s Disease - Everything you Need to Know 2022. [DOI: 10.5772/intechopen.96623] [Reference Citation Analysis]
45 Nabizadeh F, Pirahesh K, Valizadeh P. REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson’s disease: a cross-sectional and longitudinal study. J Neurol. [DOI: 10.1007/s00415-022-11120-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Zheng Y, Yu Z, Zhao J, Cai H, Wang Z, Wang X, Feng T. Oral Mucosa Derived α−Synuclein as a Potential Diagnostic Biomarker for Parkinson′s Disease. Front Aging Neurosci 2022;14:867528. [DOI: 10.3389/fnagi.2022.867528] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Giampietri L, Belli E, Beatino MF, Giannoni S, Palermo G, Campese N, Tognoni G, Siciliano G, Ceravolo R, De Luca C, Baldacci F. Fluid Biomarkers in Alzheimer’s Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments. Diagnostics 2022;12:796. [DOI: 10.3390/diagnostics12040796] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
48 Tönges L, Kwon EH, Klebe S. Monogenetic Forms of Parkinson’s Disease – Bridging the Gap Between Genetics and Biomarkers. Front Aging Neurosci 2022;14:822949. [DOI: 10.3389/fnagi.2022.822949] [Reference Citation Analysis]
49 Zhang W, Shen J, Wang Y, Cai K, Zhang Q, Cao M. Blood SSR1: A Possible Biomarker for Early Prediction of Parkinson’s Disease. Front Mol Neurosci 2022;15:762544. [DOI: 10.3389/fnmol.2022.762544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Zhang F, Yao Y, Miao N, Wang N, Xu X, Yang C. Neuroprotective effects of microRNA 124 in Parkinson's disease mice. Archives of Gerontology and Geriatrics 2022;99:104588. [DOI: 10.1016/j.archger.2021.104588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Schirinzi T, Zenuni H, Grillo P, Bovenzi R, Guerrera G, Gargano F, Pieri M, Bernardini S, Biagio Mercuri N, Battistini L, Sancesario GM. Tau and Amyloid-β Peptides in Serum of Patients With Parkinson's Disease: Correlations With CSF Levels and Clinical Parameters. Front Neurol 2022;13:748599. [DOI: 10.3389/fneur.2022.748599] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Hassin-Baer S, Cohen OS, Israeli-Korn S, Yahalom G, Benizri S, Sand D, Issachar G, Geva AB, Shani-Hershkovich R, Peremen Z. Identification of an early-stage Parkinson's disease neuromarker using event-related potentials, brain network analytics and machine-learning. PLoS One 2022;17:e0261947. [PMID: 34995285 DOI: 10.1371/journal.pone.0261947] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Kwon EH, Tennagels S, Gold R, Gerwert K, Beyer L, Tönges L. Update on CSF Biomarkers in Parkinson's Disease. Biomolecules 2022;12:329. [PMID: 35204829 DOI: 10.3390/biom12020329] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
54 Li Q, Li Z, Han X, Shen X, Wang F, Bai L, Li Z, Zhang R, Wang Y, Zhu X. A Panel of Plasma Biomarkers for Differential Diagnosis of Parkinsonian Syndromes. Front Neurosci 2022;16:805953. [DOI: 10.3389/fnins.2022.805953] [Reference Citation Analysis]
55 Chen R, Gu X, Wang X. α-Synuclein in Parkinson's disease and advances in detection. Clin Chim Acta 2022:S0009-8981(22)00056-0. [PMID: 35176268 DOI: 10.1016/j.cca.2022.02.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Fu W, Xu L, Yu Q, Fang J, Zhao G, Li Y, Pan C, Dong H, Wang D, Ren H, Guo Y, Liu Q, Liu J, Chen X. Artificial Intelligent Olfactory System for the Diagnosis of Parkinson's Disease. ACS Omega 2022;7:4001-10. [PMID: 35155895 DOI: 10.1021/acsomega.1c05060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Barba L, Paolini Paoletti F, Bellomo G, Gaetani L, Halbgebauer S, Oeckl P, Otto M, Parnetti L. Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers. Movement Disorders. [DOI: 10.1002/mds.28941] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
58 Nakajima K, Yamaguchi K, Noji M, Aguirre C, Ikenaka K, Mochizuki H, Zhou L, Ogi H, Ito T, Narita I, Gejyo F, Naiki H, Yamamoto S, Goto Y. Macromolecular crowding and supersaturation protect hemodialysis patients from the onset of dialysis-related amyloidosis.. [DOI: 10.1101/2022.02.01.478730] [Reference Citation Analysis]
59 Yu Z, Liu G, Li Y, Arkin E, Zheng Y, Feng T. Erythrocytic α-Synuclein Species for Parkinson’s Disease Diagnosis and the Correlations With Clinical Characteristics. Front Aging Neurosci 2022;14:827493. [DOI: 10.3389/fnagi.2022.827493] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Karekal A, Miocinovic S, Swann NC. Novel approaches for quantifying beta synchrony in Parkinson's disease. Exp Brain Res 2022. [PMID: 35099592 DOI: 10.1007/s00221-022-06308-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 Schumacher-schuh A, Bieger A, Borelli WV, Portley MK, Awad PS, Bandres-ciga S. Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases. Front Neurol 2022;12:792227. [DOI: 10.3389/fneur.2021.792227] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
62 Huang Y, Huang C, Zhang Q, Shen T, Sun J. Serum NFL discriminates Parkinson disease from essential tremor and reflect motor and cognition severity. BMC Neurol 2022;22:39. [PMID: 35086487 DOI: 10.1186/s12883-022-02558-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
63 Flinkman D, Hong Y, Deshpande P, Peltonen S, Kaasinen V, James P, Coffey ET. Regulators of proteostasis are translationally repressed in fibroblasts from sporadic and LRRK2-G2019S Parkinson’s patients.. [DOI: 10.1101/2022.01.17.476095] [Reference Citation Analysis]
64 Agrawal I, Tripathi P, Biswas S. Mass Spectrometry Based Protein Biomarkers and Drug Target Discovery and Clinical Diagnosis in Age-Related Progressing Neurodegenerative Diseases. Drug Metab Rev 2022;:1-17. [PMID: 35038284 DOI: 10.1080/03602532.2022.2029475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Grosso Jasutkar H, Oh SE, Mouradian MM. Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease. Pharmacol Rev 2022;74:207-37. [PMID: 35017177 DOI: 10.1124/pharmrev.120.000133] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
66 Navarro E, Udine E, de Paiva Lopes K, Parks M, Riboldi G, Schilder BM, Humphrey J, Snijders GJL, Vialle RA, Zhuang M, Sikder T, Argyrou C, Allan A, Chao MJ, Farrell K, Henderson B, Simon S, Raymond D, Elango S, Ortega RA, Shanker V, Swan M, Zhu CW, Ramdhani R, Walker RH, Tse W, Sano M, Pereira AC, Ahfeldt T, Goate AM, Bressman S, Crary JF, de Witte L, Frucht S, Saunders-Pullman R, Raj T. Dysregulation of mitochondrial and proteolysosomal genes in Parkinson's disease myeloid cells. Nat Aging 2021;1:850-63. [PMID: 35005630 DOI: 10.1038/s43587-021-00110-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
67 Kim C, Hovakimyan A, Zagorski K, Antonyan T, Petrushina I, Davtyan H, Chailyan G, Hasselmann J, Iba M, Adame A, Rockenstein E, Szabo M, Blurton-Jones M, Cribbs DH, Ghochikyan A, Masliah E, Agadjanyan MG. Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human α-synuclein: prelude for IND enabling studies. NPJ Vaccines 2022;7:1. [PMID: 35013319 DOI: 10.1038/s41541-021-00424-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
68 Yin S, Han C, Xia Y, Wan F, Hu J, Kou L, Sun Y, Wu J, Li Y, Zhou Q, Xiong N, Huang J, Wang T. Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A): Could It Be a Promising Biomarker and Therapeutic Target in Parkinson's Disease? Mol Neurobiol 2022;59:1333-44. [PMID: 34984583 DOI: 10.1007/s12035-021-02670-w] [Reference Citation Analysis]
69 Lee SH, Park SM, Yeo SS, Kwon O, Lee MK, Yoo H, Ahn EK, Jang JY, Jang JH. Parkinson's Disease Subtyping Using Clinical Features and Biomarkers: Literature Review and Preliminary Study of Subtype Clustering. Diagnostics (Basel) 2022;12:112. [PMID: 35054279 DOI: 10.3390/diagnostics12010112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
70 Surguchov A. Biomarkers in Parkinson’s Disease. Neurodegenerative Diseases Biomarkers 2022. [DOI: 10.1007/978-1-0716-1712-0_7] [Cited by in Crossref: 7] [Article Influence: 7.0] [Reference Citation Analysis]
71 Manzanares J, Sala F, Gutiérrez MSG, Rueda FN. Biomarkers. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00060-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Silva-costa LC, Smith BJ. Post-translational Modifications in Brain Diseases: A Future for Biomarkers. Advances in Experimental Medicine and Biology 2022. [DOI: 10.1007/978-3-031-05460-0_10] [Reference Citation Analysis]
73 Lin WT, Shaw JS, Cheng FY, Chen PH. Plasma total tau predicts executive dysfunction in Parkinson's disease. Acta Neurol Scand 2022;145:30-7. [PMID: 34398474 DOI: 10.1111/ane.13517] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
74 Chethana HP, Hemachandra G, Sidhu A. Biomarkers: Potential Perspectives in Detection, Diagnosis, and Prognosis of Neurodegenerative Disorders. Functional Foods and Therapeutic Strategies for Neurodegenerative Disorders 2022. [DOI: 10.1007/978-981-16-6703-9_12] [Reference Citation Analysis]
75 Chen WR, Chen JC, Chang SY, Chao CT, Wu YR, Chen CM, Chou C. Phosphorylated α-synuclein in diluted human serum a biomarker for Parkinson's disease. Biomed J 2021:S2319-4170(21)00182-7. [PMID: 34974168 DOI: 10.1016/j.bj.2021.12.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Winchester L, Lawton M, Barber I, Ash J, Liu B, Evetts S, Hopkins-jones L, Lewis S, Bresner C, Vingill S, Malpartida AB, Williams N, Gentlemen S, Wade-martins R, Ryan B, Holgado-nevado A, Hu M, Ben-shlomo Y, Grosset D, Lovestone S. Identification of a novel proteomic Biomarker in Parkinson’s Disease: Discovery and Replication in Blood, brain and CSF.. [DOI: 10.1101/2021.12.26.21268282] [Reference Citation Analysis]
77 Goto Y, Nakajima K, Yamaguchi K, So M, Ikenaka K, Mochizuki H, Ogi H. Development of HANABI, an ultrasonication-forced amyloid fibril inducer. Neurochem Int 2021;153:105270. [PMID: 34954259 DOI: 10.1016/j.neuint.2021.105270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
78 Yang P, Lin G, Wang M, Chen X, Huang J. Long non-coding RNA ANRIL interacts with microRNA-34a and microRNA-125a, and they all correlate with disease risk and severity of Parkinson's disease. J Clin Lab Anal 2021;:e24037. [PMID: 34921567 DOI: 10.1002/jcla.24037] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Ma X, Li S, Li C, Wang R, Chen M, Chen H, Su W. Diffusion Tensor Imaging Along the Perivascular Space Index in Different Stages of Parkinson's Disease. Front Aging Neurosci 2021;13:773951. [PMID: 34867300 DOI: 10.3389/fnagi.2021.773951] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
80 Zhao YW, Pan HX, Liu Z, Wang Y, Zeng Q, Fang ZH, Luo TF, Xu K, Wang Z, Zhou X, He R, Li B, Zhao G, Xu Q, Sun QY, Yan XX, Tan JQ, Li JC, Guo JF, Tang BS. The Association Between Lysosomal Storage Disorder Genes and Parkinson's Disease: A Large Cohort Study in Chinese Mainland Population. Front Aging Neurosci 2021;13:749109. [PMID: 34867278 DOI: 10.3389/fnagi.2021.749109] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
81 Ygland Rödström E, Mattsson-Carlgren N, Janelidze S, Hansson O, Puschmann A. Serum Neurofilament Light Chain as a Marker of Progression in Parkinson's Disease: Long-Term Observation and Implications of Clinical Subtypes. J Parkinsons Dis 2022;12:571-84. [PMID: 34806619 DOI: 10.3233/JPD-212866] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Christenson PR, Li M, Rowden G, Schwabenlander M, Wolf TM, Oh S, Larsen PA. A Field-Deployable Diagnostic Assay for the Visual Detection of Misfolded Prions.. [DOI: 10.1101/2021.11.22.469560] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Carlomagno C, Bertazioli D, Gualerzi A, Picciolini S, Andrico M, Rodà F, Meloni M, Banfi PI, Verde F, Ticozzi N, Silani V, Messina E, Bedoni M. Identification of the Raman Salivary Fingerprint of Parkinson's Disease Through the Spectroscopic- Computational Combinatory Approach. Front Neurosci 2021;15:704963. [PMID: 34764849 DOI: 10.3389/fnins.2021.704963] [Reference Citation Analysis]
84 Ma R, Johnson JHR, Tang Y, Fitzgerald MC. Analysis of Brain Protein Stability Changes in Mouse Models of Normal Aging and α-Synucleinopathy Reveals Age- and Disease-Related Differences. J Proteome Res 2021;20:5156-68. [PMID: 34606284 DOI: 10.1021/acs.jproteome.1c00653] [Reference Citation Analysis]
85 Lee J, Ma H, Kim YE. Biomarker in Parkinson’s Disease: Clinical and Biochemical Biomarker. J Korean Neurol Assoc 2021;39:287-297. [DOI: 10.17340/jkna.2021.4.4] [Reference Citation Analysis]
86 Xu K, Jiang X, Ariston Gabriel AN, Li X, Wang Y, Xu S. Evolving Landscape of Long Non-coding RNAs in Cerebrospinal Fluid: A Key Role From Diagnosis to Therapy in Brain Tumors. Front Cell Dev Biol 2021;9:737670. [PMID: 34692695 DOI: 10.3389/fcell.2021.737670] [Reference Citation Analysis]
87 Li XY, Li W, Li X, Li XR, Sun L, Yang W, Cai Y, Chen Z, Wu J, Wang C, Yu S. Alterations of Erythrocytic Phosphorylated Alpha-Synuclein in Different Subtypes and Stages of Parkinson's Disease. Front Aging Neurosci 2021;13:623977. [PMID: 34658833 DOI: 10.3389/fnagi.2021.623977] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
88 Mandala SHS, Liu TJ, Chen CM, Liu KK, Januar M, Chang YF, Lai CS, Chang KH, Liu KC. Enhanced Plasmonic Biosensor Utilizing Paired Antibody and Label-Free Fe3O4 Nanoparticles for Highly Sensitive and Selective Detection of Parkinson's α-Synuclein in Serum. Biosensors (Basel) 2021;11:402. [PMID: 34677358 DOI: 10.3390/bios11100402] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
89 Picca A, Guerra F, Calvani R, Romano R, Coelho-Júnior HJ, Bucci C, Marzetti E. Mitochondrial Dysfunction, Protein Misfolding and Neuroinflammation in Parkinson's Disease: Roads to Biomarker Discovery. Biomolecules 2021;11:1508. [PMID: 34680141 DOI: 10.3390/biom11101508] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 14.0] [Reference Citation Analysis]
90 Park DG, Kim JW, An YS, Chang J, Yoon JH. Plasma neurofilament light chain level and orthostatic hypotension in early Parkinson's disease. J Neural Transm (Vienna) 2021;128:1853-61. [PMID: 34568970 DOI: 10.1007/s00702-021-02423-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
91 Lungu C, Cedarbaum JM, Dawson TM, Dorsey ER, Faraco C, Federoff HJ, Fiske B, Fox R, Goldfine AM, Kieburtz K, Macklin EA, Matthews H, Rafaloff G, Saunders-Pullman R, Schor NF, Schwarzschild MA, Sieber BA, Simuni T, Surmeier DJ, Tamiz A, Werner MH, Wright CB, Wyse R. Seeking progress in disease modification in Parkinson disease. Parkinsonism Relat Disord 2021;90:134-41. [PMID: 34561166 DOI: 10.1016/j.parkreldis.2021.09.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
92 Roberta B, Paolo B, Massimo F, Roberto E. Unexpected (123I)FP-CIT SPECT findings: SWIDD, SWEDD and all DAT. J Neurol 2021. [PMID: 34537866 DOI: 10.1007/s00415-021-10809-x] [Reference Citation Analysis]
93 Di Lazzaro G, Ricci M, Saggio G, Costantini G, Schirinzi T, Alwardat M, Pietrosanti L, Patera M, Scalise S, Giannini F, Pisani A. Technology-based therapy-response and prognostic biomarkers in a prospective study of a de novo Parkinson's disease cohort. NPJ Parkinsons Dis 2021;7:82. [PMID: 34535672 DOI: 10.1038/s41531-021-00227-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
94 Nakajima K, Toda H, Yamaguchi K, So M, Ikenaka K, Mochizuki H, Goto Y, Ogi H. Half-Time Heat Map Reveals Ultrasonic Effects on Morphology and Kinetics of Amyloidogenic Aggregation Reaction. ACS Chem Neurosci 2021;12:3456-66. [PMID: 34467753 DOI: 10.1021/acschemneuro.1c00461] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
95 Krause K, Wulf M, Sommer P, Barkovits K, Vorgerd M, Marcus K, Eggers B. CSF Diagnostics: A Potentially Valuable Tool in Neurodegenerative and Inflammatory Disorders Involving Motor Neurons: A Review. Diagnostics (Basel) 2021;11:1522. [PMID: 34573864 DOI: 10.3390/diagnostics11091522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Kayed R, Dettmer U, Lesné SE. Soluble endogenous oligomeric α-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk. J Parkinsons Dis 2020;10:791-818. [PMID: 32508330 DOI: 10.3233/JPD-201965] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 26.0] [Reference Citation Analysis]
97 Barth M, Bacioglu M, Schwarz N, Novotny R, Brandes J, Welzer M, Mazzitelli S, Häsler LM, Schweighauser M, Wuttke TV, Kronenberg-Versteeg D, Fog K, Ambjørn M, Alik A, Melki R, Kahle PJ, Shimshek DR, Koch H, Jucker M, Tanriöver G. Microglial inclusions and neurofilament light chain release follow neuronal α-synuclein lesions in long-term brain slice cultures. Mol Neurodegener 2021;16:54. [PMID: 34380535 DOI: 10.1186/s13024-021-00471-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
98 Gopar-Cuevas Y, Duarte-Jurado AP, Diaz-Perez RN, Saucedo-Cardenas O, Loera-Arias MJ, Montes-de-Oca-Luna R, Rodriguez-Rocha H, Garcia-Garcia A. Pursuing Multiple Biomarkers for Early Idiopathic Parkinson's Disease Diagnosis. Mol Neurobiol 2021. [PMID: 34350555 DOI: 10.1007/s12035-021-02500-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
99 Craig DW, Hutchins E, Violich I, Alsop E, Gibbs JR, Levy S, Robison M, Prasad N, Foroud T, Crawford KL, Toga AW, Whitsett TG, Kim S, Casey B, Reimer A, Hutten SJ, Frasier M, Kern F, Fehlman T, Keller A, Cookson MR, Van Keuren-jensen K, Hutten S, Van Keuren-jensen K; Parkinson Progression Marker Initiative. RNA sequencing of whole blood reveals early alterations in immune cells and gene expression in Parkinson’s disease. Nat Aging 2021;1:734-47. [DOI: 10.1038/s43587-021-00088-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
100 Li S, Jia C, Li T, Le W. Hot Topics in Recent Parkinson's Disease Research: Where We are and Where We Should Go. Neurosci Bull 2021. [PMID: 34313916 DOI: 10.1007/s12264-021-00749-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
101 Drobny A, Ngo PA, Neurath MF, Zunke F, López-Posadas R. Molecular Communication Between Neuronal Networks and Intestinal Epithelial Cells in Gut Inflammation and Parkinson's Disease. Front Med (Lausanne) 2021;8:655123. [PMID: 34368179 DOI: 10.3389/fmed.2021.655123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
102 Ciobanu AM, Ionita I, Buleandra M, David IG, Popa DE, Ciucu AA, Budisteanu M. Current advances in metabolomic studies on non-motor psychiatric manifestations of Parkinson's disease (Review). Exp Ther Med 2021;22:1010. [PMID: 34345292 DOI: 10.3892/etm.2021.10443] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
103 Schirinzi T, Grillo P, Di Lazzaro G, Zenuni H, Salimei C, Dams-O'Connor K, Sancesario GM, Mercuri NB, Pisani A. Effects of head trauma and sport participation in young-onset Parkinson's disease. J Neural Transm (Vienna) 2021;128:1185-93. [PMID: 34263354 DOI: 10.1007/s00702-021-02370-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Hampel H, Cummings J, Blennow K, Gao P, Jack CR Jr, Vergallo A. Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol 2021;17:580-9. [PMID: 34239130 DOI: 10.1038/s41582-021-00520-w] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 48.0] [Reference Citation Analysis]
105 Dommershuijsen LJ, Boon AJW, Ikram MK. Probing the Pre-diagnostic Phase of Parkinson's Disease in Population-Based Studies. Front Neurol 2021;12:702502. [PMID: 34276552 DOI: 10.3389/fneur.2021.702502] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Tao D, Wang J, Song S, Cai K, Jiang M, Cheng J, Hu L, Jaffrezic-renault N, Guo Z, Pan H. Polythionine and gold nanostar-based impedimetric aptasensor for label-free detection of α-synuclein oligomers. J Appl Electrochem 2021;51:1523-33. [DOI: 10.1007/s10800-021-01589-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
107 Hansson O. Biomarkers for neurodegenerative diseases. Nat Med 2021;27:954-63. [PMID: 34083813 DOI: 10.1038/s41591-021-01382-x] [Cited by in Crossref: 102] [Cited by in F6Publishing: 119] [Article Influence: 102.0] [Reference Citation Analysis]
108 Botelho J, Machado V, Mendes JJ, Mascarenhas P. Causal Association between Periodontitis and Parkinson's Disease: A Bidirectional Mendelian Randomization Study. Genes (Basel) 2021;12:772. [PMID: 34069479 DOI: 10.3390/genes12050772] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
109 Chung CC, Chan L, Chen JH, Hung YC, Hong CT. Plasma Extracellular Vesicle α-Synuclein Level in Patients with Parkinson's Disease. Biomolecules 2021;11:744. [PMID: 34067663 DOI: 10.3390/biom11050744] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
110 Lake J, Storm CS, Makarious MB, Bandres-Ciga S. Genetic and Transcriptomic Biomarkers in Neurodegenerative Diseases: Current Situation and the Road Ahead. Cells 2021;10:1030. [PMID: 33925602 DOI: 10.3390/cells10051030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
111 Menculini G, Chipi E, Paolini Paoletti F, Gaetani L, Nigro P, Simoni S, Mancini A, Tambasco N, Di Filippo M, Tortorella A, Parnetti L. Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis. Int J Mol Sci 2021;22:4440. [PMID: 33922780 DOI: 10.3390/ijms22094440] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
112 Prasuhn J, Brüggemann N. Genotype-driven therapeutic developments in Parkinson's disease. Mol Med 2021;27:42. [PMID: 33874883 DOI: 10.1186/s10020-021-00281-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
113 He S, Wang F, Yung KKL, Zhang S, Qu S. Effects of α-Synuclein-Associated Post-Translational Modifications in Parkinson's Disease. ACS Chem Neurosci 2021;12:1061-71. [PMID: 33769791 DOI: 10.1021/acschemneuro.1c00028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 13.0] [Reference Citation Analysis]
114 Cesario A, D'Oria M, Bove F, Privitera G, Boškoski I, Pedicino D, Boldrini L, Erra C, Loreti C, Liuzzo G, Crea F, Armuzzi A, Gasbarrini A, Calabresi P, Padua L, Costamagna G, Antonelli M, Valentini V, Auffray C, Scambia G. Personalized Clinical Phenotyping through Systems Medicine and Artificial Intelligence. J Pers Med 2021;11:265. [PMID: 33918214 DOI: 10.3390/jpm11040265] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
115 Cui H, Wang W, Zheng X, Xia D, Liu H, Qin C, Tian H, Teng J. Decreased AQP4 Expression Aggravates ɑ-Synuclein Pathology in Parkinson's Disease Mice, Possibly via Impaired Glymphatic Clearance. J Mol Neurosci 2021. [PMID: 33772424 DOI: 10.1007/s12031-021-01836-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
116 Du T, Wang L, Liu W, Zhu G, Chen Y, Zhang J. Biomarkers and the Role of α-Synuclein in Parkinson's Disease. Front Aging Neurosci 2021;13:645996. [PMID: 33833675 DOI: 10.3389/fnagi.2021.645996] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
117 Liu X, Wang Q, Yang Y, Stewart T, Shi M, Soltys D, Liu G, Thorland E, Cilento EM, Hou Y, Liu Z, Feng T, Zhang J. Reduced erythrocytic CHCHD2 mRNA is associated with brain pathology of Parkinson's disease. Acta Neuropathol Commun 2021;9:37. [PMID: 33685516 DOI: 10.1186/s40478-021-01133-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
118 Abdi IY, Majbour NK, Willemse EAJ, van de Berg WDJ, Mollenhauer B, Teunissen CE, El-Agnaf OM. Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein. Front Aging Neurosci 2021;13:638718. [PMID: 33762924 DOI: 10.3389/fnagi.2021.638718] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
119 Tigchelaar C, Atmosoerodjo SD, van Faassen M, Wardenaar KJ, De Deyn PP, Schoevers RA, Kema IP, Absalom AR. The Anaesthetic Biobank of Cerebrospinal fluid: a unique repository for neuroscientific biomarker research. Ann Transl Med 2021;9:455. [PMID: 33850852 DOI: 10.21037/atm-20-4498] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
120 Morató X, Garcia-Esparcia P, Argerich J, Llorens F, Zerr I, Paslawski W, Borràs E, Sabidó E, Petäjä-Repo UE, Fernández-Dueñas V, Ferrer I, Svenningsson P, Ciruela F. Ecto-GPR37: a potential biomarker for Parkinson's disease. Transl Neurodegener 2021;10:8. [PMID: 33637132 DOI: 10.1186/s40035-021-00232-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
121 Vissers MFJM, Heuberger JAAC, Groeneveld GJ. Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders. Int J Mol Sci 2021;22:1615. [PMID: 33562713 DOI: 10.3390/ijms22041615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
122 Zenuni H, Grillo P, Sancesario GM, Bernardini S, Mercuri NB, Schirinzi T. How Comorbidity Reflects on Cerebrospinal Fluid Biomarkers of Neurodegeneration in Aging. J Alzheimers Dis Rep 2021;5:87-92. [PMID: 33681720 DOI: 10.3233/ADR-200280] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Ma LY, Tian Y, Pan CR, Chen ZL, Ling Y, Ren K, Li JS, Feng T. Motor Progression in Early-Stage Parkinson's Disease: A Clinical Prediction Model and the Role of Cerebrospinal Fluid Biomarkers. Front Aging Neurosci 2020;12:627199. [PMID: 33568988 DOI: 10.3389/fnagi.2020.627199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
124 Aghila Rani KG, Hamad MA, Zaher DM, Sieburth SM, Madani N, Al-Tel TH. Drug development post COVID-19 pandemic: toward a better system to meet current and future global health challenges. Expert Opin Drug Discov 2021;16:365-71. [PMID: 33356641 DOI: 10.1080/17460441.2021.1854221] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
125 Van Hulle C, Jonaitis EM, Betthauser TJ, Batrla R, Wild N, Kollmorgen G, Andreasson U, Okonkwo O, Bendlin BB, Asthana S, Carlsson CM, Johnson SC, Zetterberg H, Blennow K. An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum. Alzheimers Dement 2021;17:431-45. [PMID: 33336877 DOI: 10.1002/alz.12204] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 14.0] [Reference Citation Analysis]
126 Guo P, Wang RD, Lian TH, Ding DY, Zhang YN, Zhang WJ, Li DN, Li LX, Li JH, Guan HY, Yu SY, Liu L, Hu Y, Zuo LJ, Yu QJ, Wang XM, Zhang W. Olfactory Dysfunction and Its Association With Neuropathologic Proteins in Cerebrospinal Fluid From Patients With Parkinson Disease. Front Aging Neurosci 2020;12:594324. [PMID: 33362530 DOI: 10.3389/fnagi.2020.594324] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
127 Mattsson-Carlgren N, Palmqvist S, Blennow K, Hansson O. Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. Nat Commun 2020;11:6252. [PMID: 33288742 DOI: 10.1038/s41467-020-19957-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
128 Chung CC, Chan L, Chen JH, Bamodu OA, Hong CT. Neurofilament light chain level in plasma extracellular vesicles and Parkinson's disease. Ther Adv Neurol Disord 2020;13:1756286420975917. [PMID: 33335563 DOI: 10.1177/1756286420975917] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
129 Manfredsson FP, Polinski NK, Subramanian T, Boulis N, Wakeman DR, Mandel RJ. The Future of GDNF in Parkinson's Disease. Front Aging Neurosci 2020;12:593572. [PMID: 33364933 DOI: 10.3389/fnagi.2020.593572] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
130 Fang Y, Gu LY, Tian J, Dai SB, Chen Y, Zheng R, Si XL, Jin CY, Song Z, Yan YP, Yin XZ, Pu JL, Zhang BR. MRI-visible perivascular spaces are associated with cerebrospinal fluid biomarkers in Parkinson's disease. Aging (Albany NY) 2020;12:25805-18. [PMID: 33234732 DOI: 10.18632/aging.104200] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
131 Gao A. Identification of Blood-based Biomarkers for Early Stage Parkinson’s Disease.. [DOI: 10.1101/2020.10.22.20217893] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
132 Farotti L, Paolini Paoletti F, Simoni S, Parnetti L. Unraveling Pathophysiological Mechanisms of Parkinson's Disease: Contribution of CSF Biomarkers. Biomark Insights 2020;15:1177271920964077. [PMID: 33110345 DOI: 10.1177/1177271920964077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
133 Magrinelli F, Tinazzi M, Bhatia KP. Toward an Early Real‐Time Quaking‐Induced Conversion–Based Diagnostic Biomarker for Lewy Body–Related Synucleinopathies. Mov Disord Clin Pract 2020;7:780-781. [DOI: 10.1002/mdc3.13050] [Reference Citation Analysis]
134 Barbariga M, Zanardi A, Curnis F, Conti A, Boselli D, Di Terlizzi S, Alessio M. Ceruloplasmin oxidized and deamidated by Parkinson's disease cerebrospinal fluid induces epithelial cells proliferation arrest and apoptosis. Sci Rep 2020;10:15507. [PMID: 32968118 DOI: 10.1038/s41598-020-72447-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
135 Schaeffer E, Kluge A, Böttner M, Zunke F, Cossais F, Berg D, Arnold P. Alpha Synuclein Connects the Gut-Brain Axis in Parkinson's Disease Patients - A View on Clinical Aspects, Cellular Pathology and Analytical Methodology. Front Cell Dev Biol 2020;8:573696. [PMID: 33015066 DOI: 10.3389/fcell.2020.573696] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 13.0] [Reference Citation Analysis]
136 Shinotoh H, Tokuda T. Systemic Synuclein Sampling Study toward a Parkinson disease biomarker. Neurology 2020;95:373-374. [DOI: 10.1212/wnl.0000000000010428] [Reference Citation Analysis]
137 Irrera N, Russo M, Pallio G, Bitto A, Mannino F, Minutoli L, Altavilla D, Squadrito F. The Role of NLRP3 Inflammasome in the Pathogenesis of Traumatic Brain Injury. Int J Mol Sci 2020;21:E6204. [PMID: 32867310 DOI: 10.3390/ijms21176204] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 15.5] [Reference Citation Analysis]
138 Smedinga M, Darweesh SKL, Bloem BR, Post B, Richard E. Towards early disease modification of Parkinson's disease: a review of lessons learned in the Alzheimer field. J Neurol 2021;268:724-33. [PMID: 32809153 DOI: 10.1007/s00415-020-10162-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
139 Wang L, Cheng W, Rolls ET, Dai F, Gong W, Du J, Zhang W, Wang S, Liu F, Wang J, Brown P, Feng J. Association of specific biotypes in patients with Parkinson disease and disease progression. Neurology 2020;95:e1445-60. [PMID: 32817178 DOI: 10.1212/WNL.0000000000010498] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
140 Navarro E, Udine E, de Paiva Lopes K, Parks M, Riboldi G, Schilder BM, Humphrey J, Snijders GJL, Vialle RA, Zhuang M, Sikder T, Argyrou C, Allan A, Chao M, Farrell K, Henderson B, Simon S, Raymond D, Elango S, Ortega RA, Shanker V, Swan M, Zhu CW, Ramdhani R, Walker RH, Tse W, Sano M, Pereira AC, Ahfeldt T, Goate AM, Bressman S, Crary JF, de Witte L, Frucht S, Saunders-pullman R, Raj T. Discordant transcriptional signatures of mitochondrial genes in Parkinson’s disease human myeloid cells.. [DOI: 10.1101/2020.07.20.212407] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
141 Papuć E, Rejdak K. Increased Cerebrospinal Fluid S100B and NSE Reflect Neuronal and Glial Damage in Parkinson's Disease. Front Aging Neurosci 2020;12:156. [PMID: 32792937 DOI: 10.3389/fnagi.2020.00156] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
142 Aubignat M, Tir M, Krystkowiak P. [Non-motor symptoms of Parkinson's disease from pathophysiology to early diagnosis]. Rev Med Interne 2021;42:251-7. [PMID: 32680717 DOI: 10.1016/j.revmed.2020.06.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
143 Lessons from Oncology. Brain Fables 2020. [DOI: 10.1017/9781108888202.010] [Reference Citation Analysis]
144 Epilogue. Brain Fables 2020. [DOI: 10.1017/9781108888202.018] [Reference Citation Analysis]
145 Challenges Viewed from Afar. Brain Fables 2020. [DOI: 10.1017/9781108888202.015] [Reference Citation Analysis]
146 Espay A, Stecher B. Brain Fables. 2020. [DOI: 10.1017/9781108888202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
147 The Scientific and Lay Narratives. Brain Fables 2020. [DOI: 10.1017/9781108888202.014] [Reference Citation Analysis]
148 The Moonshot: Population-Based Studies of Aging. Brain Fables 2020. [DOI: 10.1017/9781108888202.016] [Reference Citation Analysis]
149 Our Living Dissonance. Brain Fables 2020. [DOI: 10.1017/9781108888202.013] [Reference Citation Analysis]
150 Index. Brain Fables 2020. [DOI: 10.1017/9781108888202.021] [Reference Citation Analysis]
151 Note Added at Press Time – Reviving LOF. Brain Fables 2020. [DOI: 10.1017/9781108888202.019] [Reference Citation Analysis]
152 Biomarkers: The Promise and the Fallacy. Brain Fables 2020. [DOI: 10.1017/9781108888202.009] [Reference Citation Analysis]
153 Preface 1 – The Question. Brain Fables 2020. [DOI: 10.1017/9781108888202.001] [Reference Citation Analysis]
154 References. Brain Fables 2020. [DOI: 10.1017/9781108888202.020] [Reference Citation Analysis]
155 Disease Subtypes: The Promise and the Fallacy. Brain Fables 2020. [DOI: 10.1017/9781108888202.006] [Reference Citation Analysis]
156 The Fault in Our Models. Brain Fables 2020. [DOI: 10.1017/9781108888202.008] [Reference Citation Analysis]
157 Preface 2 – Enter Patient. Brain Fables 2020. [DOI: 10.1017/9781108888202.002] [Reference Citation Analysis]
158 Symptomatic vs. Disease-Modifying Therapies. Brain Fables 2020. [DOI: 10.1017/9781108888202.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
159 Disease “Redefinition”: A Tough Pill to Swallow. Brain Fables 2020. [DOI: 10.1017/9781108888202.005] [Reference Citation Analysis]
160 Protein Paradox. Brain Fables 2020. [DOI: 10.1017/9781108888202.007] [Reference Citation Analysis]
161 Predictions for the 2020s and Beyond. Brain Fables 2020. [DOI: 10.1017/9781108888202.017] [Reference Citation Analysis]
162 The Shaky Six and the “Second Reality”. Brain Fables 2020. [DOI: 10.1017/9781108888202.003] [Reference Citation Analysis]
163 Pieces of a Puzzle? Brain Fables 2020. [DOI: 10.1017/9781108888202.004] [Reference Citation Analysis]
164 The Hypothesis That Refuses to Die. Brain Fables 2020. [DOI: 10.1017/9781108888202.012] [Reference Citation Analysis]
165 Rossi M, Candelise N, Baiardi S, Capellari S, Giannini G, Orrù CD, Antelmi E, Mammana A, Hughson AG, Calandra-Buonaura G, Ladogana A, Plazzi G, Cortelli P, Caughey B, Parchi P. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol 2020;140:49-62. [PMID: 32342188 DOI: 10.1007/s00401-020-02160-8] [Cited by in Crossref: 113] [Cited by in F6Publishing: 88] [Article Influence: 56.5] [Reference Citation Analysis]
166 Wu C, Garden PM, Walt DR. Ultrasensitive Detection of Attomolar Protein Concentrations by Dropcast Single Molecule Assays. J Am Chem Soc 2020;142:12314-23. [PMID: 32602703 DOI: 10.1021/jacs.0c04331] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 24.0] [Reference Citation Analysis]
167 Loeffler DA, Aasly JO, LeWitt PA, Coffey MP. What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson's Disease Patients and Healthy Subjects with Parkinson's-Associated LRRK2 Mutations? J Parkinsons Dis 2019;9:467-88. [PMID: 31322581 DOI: 10.3233/JPD-191630] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
168 Gerdes C, Waal N, Offner T, Fornasiero EF, Wender N, Verbarg H, Manzini I, Trenkwalder C, Mollenhauer B, Strohäker T, Zweckstetter M, Becker S, Rizzoli SO, Basmanav FB, Opazo F. A nanobody-based fluorescent reporter reveals human α-synuclein in the cell cytosol. Nat Commun 2020;11:2729. [PMID: 32483166 DOI: 10.1038/s41467-020-16575-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
169 Krainer G, Saar KL, Arter WE, Welsh TJ, Czekalska MA, Jacquat RP, Peter Q, Traberg WC, Pujari A, Jayaram AK, Challa P, Taylor CG, van der Linden L, Franzmann T, Owens RM, Alberti S, Klenerman D, Knowles TP. Direct digital sensing of protein biomarkers in solution.. [DOI: 10.1101/2020.05.24.113498] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
170 Zhang X, Zhang Y, Li R, Zhu L, Fu B, Yan T. Salidroside ameliorates Parkinson's disease by inhibiting NLRP3-dependent pyroptosis. Aging (Albany NY) 2020;12:9405-26. [PMID: 32432571 DOI: 10.18632/aging.103215] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 18.5] [Reference Citation Analysis]
171 Christine CW, Auinger P, Saleh N, Tian M, Bottiglieri T, Arning E, Tran NK, Ueland PM, Green R; Parkinson Study Group-DATATOP Investigators. Relationship of Cerebrospinal Fluid Vitamin B12 Status Markers With Parkinson's Disease Progression. Mov Disord 2020;35:1466-71. [PMID: 32407590 DOI: 10.1002/mds.28073] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
172 Majbour NK, Aasly JO, Hustad E, Thomas MA, Vaikath NN, Elkum N, van de Berg WDJ, Tokuda T, Mollenhauer B, Berendse HW, El-Agnaf OMA. CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers. Transl Neurodegener 2020;9:15. [PMID: 32375873 DOI: 10.1186/s40035-020-00192-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
173 Parish AL, Kim J. The Role of the Primary Care Provider in Work-up and Management of Parkinson Disease. Advances in Family Practice Nursing 2020;2:37-47. [DOI: 10.1016/j.yfpn.2019.12.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
174 Park SA, Han SM, Kim CE. New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer's disease. Exp Mol Med 2020;52:556-68. [PMID: 32284537 DOI: 10.1038/s12276-020-0418-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 22.0] [Reference Citation Analysis]
175 Anjo SI, Dos Santos PV, Rosado L, Baltazar G, Baldeiras I, Pires D, Gomes A, Januário C, Castelo-Branco M, Grãos M, Manadas B. A different vision of translational research in biomarker discovery: a pilot study on circulatory mitochondrial proteins as Parkinson's disease potential biomarkers. Transl Neurodegener 2020;9:11. [PMID: 32266064 DOI: 10.1186/s40035-020-00188-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
176 Mondello S, Salama MM, Mohamed WMY, Kobeissy FH. Editorial: Biomarkers in Neurology. Front Neurol 2020;11:190. [PMID: 32256443 DOI: 10.3389/fneur.2020.00190] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
177 Obrocki P, Khatun A, Ness D, Senkevich K, Hanrieder J, Capraro F, Mattsson N, Andreasson U, Portelius E, Ashton NJ, Blennow K, Schöll M, Paterson RW, Schott JM, Zetterberg H. Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg. Alzheimers Res Ther 2020;12:20. [PMID: 32111242 DOI: 10.1186/s13195-020-00586-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
178 Chiasserini D, Bijnsdorp I, Bellomo G, Orvietani PL, Piersma SR, Pham TV, Parnetti L, Jiménez CR. Proteomic analysis of extracellular vesicles in cerebrospinal fluid of patients with Alzheimer’s disease.. [DOI: 10.1101/2020.02.22.20026609] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
179 Caminati G, Procacci P. Mounting evidence of FKBP12 implication in neurodegeneration. Neural Regen Res 2020;15:2195. [DOI: 10.4103/1673-5374.284980] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
180 Mandal S, Guzmán-sáenz A, Haiminen N, Basu S, Parida L. A Topological Data Analysis Approach on Predicting Phenotypes from Gene Expression Data. Algorithms for Computational Biology 2020. [DOI: 10.1007/978-3-030-42266-0_14] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
181 Oosterveld LP, Verberk IMW, Majbour NK, El-Agnaf OM, Weinstein HC, Berendse HW, Teunissen CE, van de Berg WDJ. CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls. Mov Disord 2020;35:288-95. [PMID: 31737952 DOI: 10.1002/mds.27897] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 14.0] [Reference Citation Analysis]
182 Gerdes C, Waal N, Offner T, Fornasiero EF, Wender N, Verbarg H, Manzini I, Trenkwalder C, Mollenhauer B, Strohäker T, Zweckstetter M, Becker S, Rizzoli SO, Basmanav B, Opazo F. A nanobody-based fluorescent reporter reveals human α-synuclein in the cell cytosol.. [DOI: 10.1101/846014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
183 Xicoy H, Peñuelas N, Vila M, Laguna A. Autophagic- and Lysosomal-Related Biomarkers for Parkinson's Disease: Lights and Shadows. Cells 2019;8:E1317. [PMID: 31731485 DOI: 10.3390/cells8111317] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
184 Li T, Le W. Biomarkers for Parkinson's Disease: How Good Are They? Neurosci Bull 2020;36:183-94. [PMID: 31646434 DOI: 10.1007/s12264-019-00433-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
185 Ryman SG, Poston KL. MRI biomarkers of motor and non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2020;73:85-93. [PMID: 31629653 DOI: 10.1016/j.parkreldis.2019.10.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
186 Lin CH, Liu HC, Yang SY, Yang KC, Wu CC, Chiu MJ. Plasma pS129-α-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson's Disease. J Clin Med 2019;8:E1601. [PMID: 31623323 DOI: 10.3390/jcm8101601] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
187 Boylan LS, Chiò A. Divining progression in Parkinson disease with a blood test: NfL. Neurology 2019;93:471-2. [PMID: 31420460 DOI: 10.1212/WNL.0000000000008087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
188 Cariulo C, Martufi P, Verani M, Azzollini L, Bruni G, Weiss A, Deguire SM, Lashuel HA, Scaricamazza E, Sancesario GM, Schirinzi T, Mercuri NB, Sancesario G, Caricasole A, Petricca L. Phospho-S129 Alpha-Synuclein Is Present in Human Plasma but Not in Cerebrospinal Fluid as Determined by an Ultrasensitive Immunoassay. Front Neurosci 2019;13:889. [PMID: 31507364 DOI: 10.3389/fnins.2019.00889] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]